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and platelet activation on the surfaces of 
these devices lead to clot formation. This, 
in turn, causes device failure and thrombo-
embolic complications. The most common 
solution to this problem is systemic antico-
agulation, but this leads to bleeding compli-
cations that can also contribute to patient 
morbidity and mortality. [ 1–3 ] Anticoagula-
tion that is limited only upon device sur-
faces could remedy these shortcomings. 
 Two methods of surface focused anti-
coagulation have demonstrated some 
promise in reducing coagulation: surface 
coatings designed to limit nonspecifi c pro-
tein adsorption and anti-platelet surface 
NO release. Surface coatings only reduce 
coagulation in the device and thus have no 
systemic anticoagulant effect. Various com-
mercial anti-thrombogenic coatings have 
shown better preservation of platelet counts 
than the uncoated control surface [ 4,5 ] during 
short-term applications. However, these sur-
face coatings have not yet proven suffi cient 
to allow the elimination of systemic antico-
agulation or long-term use of high surface area artifi cial organs 
without signifi cant decrease in systemic platelet concentration. [ 6,7 ] 
 Nitric oxide is released from biomaterials into fl owing 
blood, [ 8–12 ] but has a short half-life of 2–5 seconds [ 8 ] in blood 
prior to being scavenged. Thus, its systemic effects are minor, 
and it has been examined as a means to focus anticoagulation 
at biomaterials’ surfaces rather than systemically. Several means 
of supplying surface NO fl ux have been tested. They include 
NO release from a stored pool in the biomaterial, NO genera-
tion from endogenous sources in blood, and NO delivery via 
the gas fl ow in artifi cial lungs. [ 9–12 ] Early studies examining the 
latter approach were largely unsuccessful. These studies did not 
quantify surface NO fl ux, and it was likely insuffi cient. [ 13 ] More 
recent studies with proven, endothelial levels of NO fl ux (>2 × 
10 −10 mol/min/cm 2 ) have been successful, reducing platelet 
adhesion in tubing and catheters by approximately 40%, [ 9,10 ] 
and markedly reducing coagulation and increasing longevity in 
artifi cial lungs. [ 12 ] Although positive, these studies were all for a 
period of 4 hours. Longer-term effectiveness in these settings is 
unknown. Additionally, use of NO in high surface area artifi cial 
organs could lead to excessive generation of methemoglobin in 
the blood, limiting the possible fl ux rates, and anticoagulation. 
 In this study, we hypothesize that the combination of anti-
adsorptive coatings and surface NO fl ux will lead to more 
 This study examines platelet adhesion on surfaces that combine coatings to 
limit protein adsorption along with “anti-platelet” nitric oxide (NO) release. 
Uncoated and poly-2-methoxyethylacrylate (PMEA) coated, gas permeable 
polypropylene (PP) membranes were placed in a bioreactor to separate 
plasma and gas fl ows. Nitrogen with 100/500/1000 ppm of NO was supplied 
to the gas side as a proof of concept. On the plasma side, platelet rich plasma 
(PRP, 1 × 108 cell/mL) was recirculated at low (60)/high (300) fl ows (mL/
min). After 8 hours, adsorbed platelets on PP was quantifi ed via a lactate 
dehydrogenase assay. Compared to plain PP, the PMEA coating alone 
reduced adsorption by 17.4 ± 9.2% and 29.6 ± 16.6% at low and high fl ow 
(p < 0.05), respectively. NO was more effective at low plasma fl ow. At 100 and 
500 ppm of NO, adsorption fell by 37.9 ± 6.1% and 100 ± 4.7%, (p < 0.001), 
on plain PP. At high fl ow with 100, 500, and 1000 ppm of NO, adsorption 
reduced by 17.9 ± 17.8%, 46.4 ± 23.2%, and 100 ± 4.8%, (p < 0.001), respec-
tively. On PMEA-coated PP with only 100 ppm, adsorption fell by 69.7 ± 6.8 
and 65.6% ± 16.9%, (p < 0.001), at low and high fl ows respectively. Therefore, 
the combination of an anti-adsorptive coating with NO has great potential to 
reduce platelet adhesion and coagulation at biomaterial surfaces. 
 1.  Introduction 
 Various artifi cial organs, catheters, stents, and other medical 
devices operate under long-term blood contact. Protein adsorption 
DOI: 10.1002/admi.201400012
 S. Gupta 
 College of Human Medicine 
 Michigan State University 
 E Lansing ,  MI  48824 ,  USA 
 K. A. Amoako 
 Departments of Internal Medicine 
 Cardiology  University of Michigan 
 Ann Arbor ,  MI  48109 ,  USA 
 A. Suhaib 
 Department of Biomedical Engineering 
 University of Michigan 
 Ann Arbor ,  MI  48109 ,  USA 
 K. E. Cook[+] 
 Department of Biomedical Engineering 
 Carnegie Mellon University 
 Pittsburgh ,  PA  15213 ,  USA 
E-mail:  keicook@andrew.cmu.edu 
 [+]Current address: Department of Biomedical Engineering, 3321 PTC, 
700 Technology Drive, Pittsburgh, PA 15213. 
Adv. Mater. Interfaces 2014, 1, 1400012
www.advmatinterfaces.dewww.MaterialsViews.com
FU
LL
 P
A
P
ER
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1400012 (2 of 7)
effective surface-focused anticoagulation. Anti-adsorptive coat-
ings would limit protein adsorption, thereby reducing platelet 
activation induced via surface adhesion or surface-generation of 
agonists. In theory, a lower level of NO could then be used to 
anesthetize the limited number of platelets that adhere to the 
surface or contact the lower levels of soluble agonists. In this 
way, the surface would operate more like the endothelium, which 
uses several simultaneous methods to control coagulation. [ 14–16 ] 
 To examine this hypothesis, bioreactors were constructed 
with gas permeable polypropylene membranes. The bioreac-
tors were then used to determine the relationship between 
sweep gas concentration and NO fl ux. Platelet rich plasma was 
recirculated over polypropylene membranes that were either 
uncoated or coated with PMEA. Various levels of NO fl ux at 
varying plasma fl ow rates were then examined with each type of 
membrane, and the number of adsorbed platelets was used as 
the primary index of biocompatibility. 
 2.  Materials and Methods 
 2.1.  Bioreactor Test Circuits 
 Several means of surface NO delivery is possible. [ 9,11–13 ] For 
simplicity, custom-built polycarbonate bioreactors were created 
in order to simulate surface NO fl ux ( Figure  1 ). Each bioreactor 
consisted of a two-piece fl ow cell that sandwiches a gas perme-
able polypropylene membrane with a surface area of 7.7 cm 2 . 
The membrane partitions the fl ow cell into a blood plasma fl ow 
side and a gas fl ow side. The bioreactor was then used to study 
NO fl ux from the surface as well as surface platelet deposition 
under a variety of conditions. 
 2.2.  Nitric Oxide (NO) Flux Measurements 
 Prior to examining platelet adhesion, the relationship between 
sweep gas NO concentration and bioreactor membrane NO fl ux 
was determined using PBS within the bioreactor circuits. This 
is a conservative estimate of NO fl ux during our plasma experi-
ments, below. In plasma, some NO would bind to proteins, 
leading to a slightly higher effective diffusivity. A total of 55 mL 
of PBS (25 mL to fi ll bioreactor + 30 mL reservoir) was recir-
culated on one side of the membrane at high fl ow (300 mL/
min) and at low fl ow (60 mL/min), while N 2 with 100 ppm and 
500 ppm of NO fl owed over the opposite surface. PBS samples 
were taken before initiating fl ow and at 3 min, 5 min, 10 min, 
20 min and 30 min of recirculation. PBS NO concentrations 
were immediately measured with a Sievers Nitric Oxide Ana-
lyzer 280i (GE Instruments, Boulder, CO) using standard wet-
phase measurement methods. The NO fl ux at each sampling 
time,  J NO t = x (mol/min/cm 2 ), was fi rst calculated as the change 
in NO concentration between current and previous samples 
divided by time elapsed between sampling times and mem-
brane surface area.  J NO at each time point was then used to cal-
culate NO mass transfer coeffi cient,  Kc (cm/min), for each time 
point.  Kc was calculated as  Kc =  J NO /([NO] max – [NO] measured ), 
where [NO] max (mol/mL) is the maximum achievable [NO] in 
PBS at the temperature and pressure from the NO gas concen-
tration. We used 1.94 × 10 −3 mol L −1 atm −1 as a reference value 
for the solubility of NO in PBS. [ 17 ] The  Kc values at all sam-
pling times were plotted and a linear regression line was used 
to estimate NO’s mass transfer coeffi cient at the onset of NO 
gas fl ow  Kc ( t = 0). Having determined  Kc ( t = 0) and [NO] max , 
the  J NO through the tested PP membranes was calculated as 
 J NO =  Kc ( t = 0) x [NO] max . 
 2.3.  Platelet Adhesion Studies: Effect of NO Flux and Surface 
Coating 
 All platelet adhesion studies utilized freshly drawn sheep 
plasma. The animal handling and surgical procedures were 
approved by the University Committee on the Use and Care of 
Animals in accordance with University of Michigan and federal 
regulations. Sheep whole blood was gravity drawn into a blood 
transfer blood bag (1:10 acid citrate dextrose 4% (ACD) antico-
agulant, Sigma Aldrich St Louis MO). Whole blood from the 
bag was then carefully transferred to 50 mL centrifuge tubes 
and centrifuged at 730 rpm for 20 min to generate PRP. Platelet 
rich plasma was then recovered, and the remaining blood was 
centrifuged at 2750 rpm for 15 min to obtain platelet poor 
plasma (PPP). A Beckman-Coulter particle counter (Z1 Coulter 
Particle Counter, Indianapolis IN) was then used to determine 
platelet counts of the PRP and PPP. The PRP and PPP were 
then mixed to obtain 1 × 10 8 cells/mL. 
 Twenty-fi ve milimeters of this mixture was injected into each 
of the three bioreactors. Each bioreactor was fi tted with a 3’’ x 
0.5’’ gas permeable PP membrane with an average pore size of 
0.1 µm (Sterlitech, Kent, WA) that was uncoated or coated with 
PMEA using standard procedures (Terumo Cardiovascular, Ann 
Arbor, MI). PMEA coating on PP membranes was confi rmed 
(See  Figure  2 ) with energy dispersive x-ray spectroscopy (EDAX 
Inc., Mahwah NJ) as previously described. [ 18 ] 
 The bioreactors were incorporated into a circuit consisting 
solely of 3/16’’ inner diameter Tygon tubing (Fisher Scientifi c, 
Pittsburg, PA). The tubing was then placed within a roller 
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 Figure 1.  Bioreactor fl ow cell; exploded view of fl ow cell showing platelet 
rich plasma (PRP) fl ow chamber, test membrane, and sweep gas fl ow 
chamber (A) and assembled bioreactor showing PRP and NO gas 
counter-current fl ow (B).
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pump (Stockert multifl ow, Baxter Century Baxter Healthcare 
Cooperation Irvine, CA). The PRP fl ow rate was set to either 
300 mL/min (high fl ow) or 60 mL/min (low fl ow) using tran-
sonic fl ow probes (Transonic Systems, Ithaca, NY). These fl ows 
are equivalent to Reynolds numbers of 1.4 (Pe = 5384) and 7.1 
(Pe = 27307), respectively. [ 19 ] Lastly, the sweep gas was nitrogen 
with either 100, 500, or 1000 ppm of NO set at a fl ow rate twice 
the PRP fl ow rate. 
 To reduce biases created by run-to-run variability, three cir-
cuits were always run simultaneously such that three experi-
mental conditions could be run with the same batch of plasma. 
In each run, three conditions were randomly chosen from all 
possible combinations of surface (PP, PMEA-coated PP, and 
PMEA-coated PP) and NO concentration (0, 100, 500, or 1000). 
After 8 hours of PRP recirculation, a 1 mL aliquot of PRP was 
obtained to test for platelet aggregation. The membranes were 
then carefully removed from the bioreactors and rinsed 3× in 
PBS using a 3mL pipette to wash away non-adhered blood 
plasma elements. The membrane was then sectioned length-
wise into two halves. One half was assayed for LDH, and the 
other half was fi xed for SEM analysis (see sections 3.6 and 3.7). 
Experimental runs with three circuits were repeated until fi ve 
experiments were performed for each coating, NO concentra-
tion, and PRP fl ow rate combination. 
 2.4.  Lactate Dehydrogenase (LDH) Assay 
 A lactate dehydrogenase (LDH) assay kit (Cayman Chemicals 
Ann Arbor, 10008882) was used to quantify platelets adhered on 
the surface of each membrane after 8 hours of PRP exposure in 
the bioreactor. Each membrane section was incubated at 37 °C 
in two mL of lysing reagent (1% Triton-X100, 0.75% Bovine 
Albumin Serum in phosphate buffered saline) for 1hr, with 
occasional agitation. The suspension was then assayed for LDH 
according to the kit manufacturer's protocol. To convert LDH 
concentration to the number of adhered cells, a calibration curve 
was fi rst constructed. PRP (7 × 10 8 platelets/mL) was serially 
diluted with PPP to achieve platelet concentrations of 4.7 × 10 8 , 
2.4 × 10 8 , 1.2 × 10 8 , 6.0 × 10 7 , 3.0 × 10 7 , 1.5 × 10 7 , and 7.5 × 
10 6 cell/mL and were assayed for LDH. A linear curve fi t was 
then used to determine the relationship between absorbance 
from LDH and number of cells. This curve was found to be 
LDH absorbance = 0.12 X platelets (X10 6 cells/mL) + 0.01, (R 2 = 0.99). 
 2.5.  SEM Analysis 
 One half of each tested membrane was fi xed with 2% gluter-
aldehyde (Sigma Aldrich, ST Louis MO) overnight and then 
dehydrated in a series of ethanol solutions and completely 
dried. The mid-section of the membrane was cut, sputter-coated 
with gold, and imaged by a Hitachi S-3200N scanning electron 
microscope (15 kV). 
 2.6.  Data and Statistical Analysis 
 Raw LDH data obtained from coated and uncoated samples 
were adjusted to remove background LDH levels. To do so, 
a control study was run using PBS only in the circuit and 
assaying these membranes for LDH in the described manner 
(n = 4). The average background LDH data was then subtracted 
from the LDH concentrations measured in all studies. Any 
results giving a number below this value were given an adjusted 
LDH value of zero. Adjusted LDH data of test samples was 
then normalized by expressing the data as a percentage of LDH 
data obtained from uncoated control PP. Lastly, the calibration 
curve between LDH and platelet count was used to determine 
the number of adhered platelets, which was then divided by the 
surface area of test sample to give platelets/cm 2 . Statistics was 
performed on normalized LDH data using the Origin statistical 
package (OriginLab, Northampton MA). Specifi cally, one-way 
analysis of variance (ANOVA) with a Tukey's post hoc analysis 
was used to compare normalized data. Statistical signifi cance 
was set to p < 0.05. Numerical values are presented as mean 
+/− standard deviation. 
 3.  Results 
 Nitric oxide concentration in water over time exhibited the charac-
teristic curve shown in  Figure  3 . The gas’ concentration in water 
steadily increased during recirculation of PBS and fl ow of NO gas. 
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 Figure 2.  Surface chemical composition and chemical spectra of plain polypropylene (A), and PMEA-coated polypropylene (B).
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After reaching the solubility limit, NO concentration remained 
fairly constant at the temperature and pressure for each test con-
dition. At low PBS fl ow,  J NO was calculated to be (2.40 ± 1.63) × 
10 −10 mol/min/cm 2 from 100 ppm sweep gas NO and (11.17 ± 
2.98) x 10 −10 mol/min/cm 2 from 500 ppm sweep gas NO. At high 
fl ow, the same  J NO were 1.70 ± 0.56 × 10 −10 mol/min/cm 2 and 
21.13 ± 1.97 × 10 −10 mol/min/cm 2 . See  Figure  4 . These values 
are similar to NO fl ux levels reported to signifi cantly inhibit clot 
formation. [ 9–11 ] 
 Platelet adsorption, (% control), on plain PP and PMEA-
coated PP at 60 mL/min PRP fl ow using several sweep gas NO 
concentrations is shown in  Figure  5 (B). Platelet adsorption on 
PMEA-coated PP without NO was 82.6 ± 9.2% of the control 
PP surface (p < 0.05). Platelet adhesion on plain PP with sweep 
gas NO at 100 and 500 was 62.1 ± 6.1% (p < 0.001) and 0 ± 
4.5% (p < 0.001). Together, PMEA and NO act synergistically to 
reduce platelet adhesion when the NO concentration is low and 
thus not completely eliminating platelet adhesion. At 100 ppm 
of NO, adhesion on PMEA coated surfaces was 30.3 ± 6.8% of 
the control. The reduction at 100 ppm is thus 69.7%, which is 
greater than the additive effects of PMEA (17.4% reduction) 
and NO (27.9% reduction) alone. 
 Figure  5 (A) shows the same experiments at high PRP fl ow 
(300 mL/min). High fl ow results showed similar qualitative 
PMEA and coating effects, but reduced effectiveness of NO. 
Platelet adsorption on PMEA-coated PP without NO was 70.4 ± 
9.5% of the control (p < 0.05). Platelet adhesion on plain PP 
with sweep gas NO at 100, 500, and 1000 ppm was 82.1 ± 17.8% 
(p < 0.05), 53.6 ± 23.2% (p < 0.05), and 0 ± 4.6% (p < 0.001). 
Thus, at these higher fl ows, a greater amount of NO is neces-
sary to create the same level of platelet inhibition. The com-
bined effect of PMEA and NO at low NO concentrations at high 
fl ows again appears greater than additive. With a PMEA coating 
and 100 ppm of NO, platelet adhesion was 34.4 ± 17.0% of the 
control. The reduction in adhesion is thus 65.6%, which is 
again greater than the additive effects of PMEA (29.6% reduc-
tion) and NO (17.9% reduction) alone. 
 Figures  5 C and 5D reorganize the data to more clearly dem-
onstrate the effect of PRP fl ow rate. Flow rate does not cause a 
consistent effect on plain PP or PMEA-coated surfaces. How-
ever, higher fl ow does consistently reduce the effectiveness 
of NO. Surface fouling as analyzed with scanning electron 
microscopy, is shown in  Figures  6 and  7 for low and high fl ows, 
respectively. The left panels show platelet adsorption on plain 
PP and the right panels similarly show adsorption on PMEA-
coated PP. In both fl ow conditions, platelet deposition was 
reduced by PMEA coating as well as increasing sweep gas NO 
concentration. In the low fl ow case, there is very little platelet 
adhesion when PMEA surfaces are combined with greater 
than 100 ppm of NO. In the high fl ow case, however, there is 
still signifi cant platelet adhesion at 500 ppm with or without 
the PMEA coating. At high fl ow, 1000 ppm is needed to largely 
eliminate platelet adhesion. 
 The platelet surface coverage, (cells/cm 2 ), on tested PP mem-
branes ( Table  1 ) was calculated using the calibration curve. It 
shows PMEA coating and NO gas resistance to platelet adsorp-
tion. Platelet adhesion on uncoated PP was 6.01 ± 0.88 × 
10 6 platelets/cm 2 and 6.49 ± 0.87 × 10 6 platelets/cm 2 at low and 
high fl ows respectively. This was reduced to below the sensi-
tivity of the LDH assay with the PMEA coating combined with 
500 ppm of NO at low fl ow or 1000 ppm of NO at high fl ow. 
 4.  Discussion 
 These results confi rm that platelet adhesion on a biomaterial 
is synergistically reduced by combining a coating intended to 
reduce protein adsorption with NO fl ux. In this study, the reduc-
tion in platelet adhesion by the coating alone was modest (18–
30%). The effect of NO alone increased with NO concentration, 
ranging from a modest 18% or 38% (high and low fl ow, respec-
tively) at 100 ppm to complete elimination of platelet binding at 
500–1000 ppm. Although the effects of PMEA and low concen-
tration NO are modest separately, together their effects are ampli-
fi ed. With 100 ppm of NO and PMEA at low fl ow, platelet binding 
was reduced 70%, greater than the sum of the reductions caused 
by PMEA and 100 ppm of NO alone (45%). With 100 ppm of 
NO and PMEA at high fl ow, platelet adhesion was reduced 66%, 
once again greater than the effect of PMEA and NO alone (48%). 
Thus, the combined effect is 18–25% greater than if their effects 
were additive, suggesting that the presence of a protein adsorp-
tion resistant coating may potentiate the effect of NO. Local fl uid 
mechanics is also shown to play a signifi cant role in the ability of 
Adv. Mater. Interfaces 2014, 1, 1400012
www.advmatinterfaces.de www.MaterialsViews.com
 Figure 3.  Nitric oxide (NO) concentration in water during recirculation of 
water at 120 mL/min and 500 ppm NO gas fl ow at 300 mL/min.
 Figure 4.  NO fl ux,  J NO , across gas permeable PP membrane after 10 min-
utes of low (60mL/min) and high (300mL/min) PBS fl ows.
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NO to inhibit platelet activation. At high fl ow rates, Peclet num-
bers are increased, and local transport of both surface generated 
procoagulants (e.g., thrombin) and NO are increased at the bio-
material surface. On a normal surface, without NO transport, 
increased fl ow typically slows clot formation due to higher pro-
coagulant transport from the surface. In this study, however, the 
effectiveness of NO is diminished by increased convective trans-
port of NO. At 60 mL/min and 300 mL/min the Peclet numbers 
are 5380 and 27300, respectively. 
 This suggests two things. First, NO should be more effective 
in stagnant regions where clots typical form in medical devices. 
Local Peclet numbers will be small, nitric oxide will accumu-
late, and this should have a greater effect than local procoagu-
lant accumulation. Second, NO will be less effective in whole 
blood. At the same Reynolds number, the Peclet number will 
be larger because of 1) higher blood viscosity (≈ 4x water) and 
2) a smaller effective NO diffusivity due to NO scavenging by 
red blood cells (RBCs). [ 20 ] The extent of this effect, however, 
will vary from application to application. In all situations, there 
will be a cell-free, exclusionary layer near the surface that con-
tains only platelet rich plasma, which may moderate the effect 
of RBCs. The thickness of this zone in laminar fl ows is on the 
order of the RBC diameter, 8 µm, but varies with local fl uid 
mechanics. [ 21–23 ] Further studies are thus necessary to examine 
the effect of RBCs on NO inhibition of platelets in various 
whole blood fl ow conditions. 
 Several other limitations should be considered in the inter-
pretation of these results. First, the test system was a closed 
in-vitro circuit. Thus, both NO concentration and surface–gen-
erated procoagulant molecules accumulate over time. If used 
 in-vivo with whole blood, this accumulation would not occur to 
the same extent due to RBC binding and by clearance of proco-
agulant molecules. 
 Second, NO delivery was provided in this study via diffu-
sion from an N 2 and NO mixture. This served as a relatively 
simple means to approximate NO release from NO donors in 
polymers [ 24 ] and estimate NO fl uxes. However, as mentioned 
previously, NO fl ux rates and local concentrations will be dif-
ferent in blood due to the presence of NO scavengers. Fur-
thermore, the effect of NO will vary slightly if NO is catalyti-
cally generated from donors in blood, [ 12,25 ] or if NO is mixed 
with O 2 immediately prior to delivery to artifi cial lungs. In the 
former case, the effect of local fl ow rate will be different, as 
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 Figure 5.  Platelet adsorption at high fl ow, 300 mL/min (A) and low fl ow, 60 mL/min (B) on PP and PMEA-coated PP membranes. Other panels show 
platelet adsorption at high and low fl ows on PP (C) and on PMEA-coated PP (D) membranes. * Indicates (p < 0.05) signifi cance.
 Figure 6.  Scanning electron micrographs of fouling levels on PP and 
PMEA-coated PP membranes with 0 -500 ppm NO gas fl ows and 60 mL/
min blood plasma fl ow.
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increased fl ow rate will also increase transport of NO donors 
to the polymer surface. In the latter, NO will be transported 
in part as nitrite or nitrate, which could reduce platelet 
inhibition. 
 The method of NO release will ultimately 
have to be chosen based on device applica-
tion. In many of devices such as catheters, 
stents, vascular patches and grafts, the bulk 
and/or surface will have to be modifi ed with 
either NO donor molecules or NO-generating 
catalysts. [ 9,12 ] Devices with NO donor mol-
ecules will have a limited duration of NO 
release that is compounded in devices with 
small material volumes. Despite the variety 
of NO donor molecules such as organic 
nitrates, metal-NO complexes, N-diazeni-
umdiolates, and synthetic S-nitrosothiols 
available, devices modifi ed with these agents 
show a limited (up to 14 days) duration of 
NO release. [ 26 ] This is a problem that must 
be solved to meet the demands of long-term 
blood-contacting devices. High capacity NO 
carrier compounds and pH-reducing addi-
tives incorporated into the bulk of these 
devices for prolonged NO release studies 
are thus being investigated. [ 26 ] Larger quan-
tities of NO can be loaded in polymers 
using high capacity NO carrier compounds. 
However, NO release from diazeniumdi-
olates increases the pH of the NO-releasing 
polymer, which in turn shuts off NO release. 
To solve this problem, slow hydrolyzing, 
acid-forming additives can be used promote 
continuous NO release by countering the 
pH increase. [ 26,27 ] Despite this, devices with 
small material volumes may never be able to 
supply suffi cient NO for applications on the 
order of weeks. To allow for long-term con-
tinuous NO fl ux, these surfaces would have 
to be modifi ed at their surface with small 
quantities of NO-generating catalysts. If nec-
essary, this generation can be supplemented 
via the infusion of stable NO donors. [ 12 ] 
 The combination of anti-fouling coatings and NO should 
also be attempted with other polymer coatings. PMEA has 
been determined to be the most effective anti-protein coating 
of the acrylate polymers, but it's also one of many low-fouling 
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 Figure 7.  Scanning electron micrographs of fouling levels on PP and PMEA-coated PP mem-
branes with 0 -1000 ppm NO gas fl ows and 300 mL/min blood plasma fl ow.
 Table 1.  Platelet surface coverage on unmodifi ed and modifi ed PP membranes. 
Surface Low Flow High Flow
 Absorbance  Surface Coverage 
 (xl0 6 cells/cm 2 )±SD 
Absorbance  Surface Coverage 
 (xl0 6 cells/cm 2 )±SD 
PP 3.5 ± 0.51 6.01 ± 0.88 3. 78 ± 0.51 6.49 ± 0.87
PMEA 2.89 ± 0.26 4.95 ± 0.45 2.66 ± 0.44 4.56 ± 0.75
PP+l00 ppm NO 2. 17 ± 0.21 3.72 ± 0.36 3.1 ± 0.68 5.32 ± 1.16
PP + 500 ppm NO 0.0 ± 0.16 0.0 ± 0.01 2.02 ± 0.88 3.46 ± 1.51
PP + l000 ppm NO — — — —
PMEA + l00 ppm NO 0.66 ± 0.19 1.12 ± 0.32 1.3 ± 0.45 2.22 ± 0.76
PMEA + 500 ppm NO 0.01 ± 0.16 0.0 ± 0.01 0.72 ± 0.05 1.22 ± 0.59
PMEA + l000 ppm NO — — — —
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polymers available. [ 28 ] Another, promising type of non-fouling 
coating are those composed of zwitterionic polymers. This 
class of polymers demonstrates far lower protein adsorp-
tion (<0.3 pg/cm 2 ) after incubation with 100% plasma and 
whole blood under static conditions. [ 29–39 ] In comparison, 
protein adsorption on PMEA coatings has been reported as 
300 pg/cm 2 . [ 40 ] Thus, zwitterionic coatings may prove even 
more effective when combined with NO, allowing for even 
greater platelet inhibition at low NO concentrations. This, in 
turn, would help avoid the metHb generation by nitric oxide. 
 5.  Conclusion 
 Alone, PMEA, protein-adsorption resistant coatings and sur-
face NO fl ux both reduce platelet adhesion on polypropylene 
membranes. When PMEA coatings and NO release were com-
bined, platelet adhesion was signifi cantly lower. Furthermore, 
the reduction in platelet adhesion was greater than what would 
be predicted by the addition of reductions in adhesion caused 
by PMEA and NO alone. Thus, combining non-fouling surface 
coatings with surface NO release acts synergistically. Future 
work should test new, ultra-low fouling coatings with different 
means of surface NO delivery. 
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